SPUTNIK V IN INDIA: RUSSIAN VACCINE | UPSC EXAM

INTRODUCTION

  • The Drugs Controller General of India approved Russia’s Coronavirus vaccine “Sputnik V” for emergency use on April 12, 2021, and the Russian is anticipated to be accessible in India by the end of May 2021, according to its India producer Dr. Reddy’s.
  • Based on clinical testing done by Indian vaccine producer Dr. Reddy’s, the expert panel approved the vaccine for emergency use permission in India.
  • With this decision, Russia’s Sputnik V vaccine has been approved for emergency use in India for the third time.
  • Some of many vaccinations are made with the mRNA technology, whereas others are made with the adenovirus technique.

WORKING AND CLINICAL TRIALS – 

  • The Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow created the Sputnik V vaccine, which employs two distinct viruses that cause the common cold (adenovirus) in humans.
  • Since the adenoviruses have been weakened, they are unable to reproduce in people and hence cannot cause illness.
  • The study participants were given the initial dosage (rAD26-), followed by the booster dose (rAD5-S) 21 days later.
  • According to the authors of a research published in The Lancet, using multiple adenovirus vectors helps create a stronger immune response than using the same vector twice because it reduces the chance of the immune system acquiring tolerance to the first vector.
  • The vaccination did not induce any allergies in the Sputnik V trial.

BASIC INFORMATION ABOUT SPUTNIK V – 

  • Sputnik uses a different vector for each of the two injections, 21 days apart in a vaccine regimen. This will also provide you longer-lasting protection than vaccinations that employ the same delivery method for both doses.
  • In liquid form, the vaccine should be kept at -18 degrees Celsius in its freeze-dried form, may be kept between 2-8 degrees Celsius in a standard refrigerator without the requirement for extra cold chain equipment.
  • Dr. Reddy’s and the Russian Direct Investment Fund collaborated in September 2020 to perform clinical studies in India.
  • RDIF has teamed with five additional Indian companies. Hetero Biopharma, Gland Pharma, Virchow Biotech, Stelis Biopharma, and Panacea Biotec are the companies involved. Their collaboration with RDIF is projected to increase India’s vaccine production capacity to about 600 million doses per year.
  • In February 2021, The Lancet released a review of the experiment, which found 91.6 percent effectiveness with no notable adverse effects and emergency vaccine delivery began in December 2020 in a number of nations, including Russia, Belarus, Argentina, Hungary, the United Arab Emirates, and Serbia.

 

Leave a Reply

Your email address will not be published. Required fields are marked *